China's CSO industry faces collapse due to anti-corruption

🔑 Enhanced Key Takeaways

• •The 2026 judicial interpretation specifically targets 'indirect bribery' via third-party service providers, effectively closing the loophole where pharmaceutical companies used CSOs to mask illicit payments as legitimate marketing expenses.
• •Major multinational pharmaceutical firms operating in China have initiated mass terminations of CSO contracts, shifting toward internalizing sales teams to maintain direct compliance oversight.
• •The 'two-invoice system' (两票制) policy, originally introduced in 2017, served as the regulatory precursor that began squeezing CSO margins by limiting the number of intermediaries in the supply chain.
• •Tax authorities have integrated data with anti-corruption agencies, using AI-driven invoice auditing to identify 'shell' CSOs that provide no actual marketing services but exist solely to generate cash for kickbacks.
• •The collapse of the CSO sector has triggered a significant talent migration, with thousands of former medical representatives moving into digital health platforms and patient support services that operate under stricter regulatory scrutiny.

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline